InpharmD™





Add Drug Information Pharmacists

Without Adding FTEs

So you can practice at top of license.

Get Started Free

Trusted by 20,000+ clinical pharmacists.

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?


Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


More than 30 of the world's best health systems hire an InpharmD™ virtual DI pharmacist, yielding:


168,534

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

Please provide a data summary for the use of Fibryga in cardiac surgery for use by anesthesia during the procedure as...
Can you summarize the differences in benzodiazepine withdrawal severity, onset, and duration for the various benzodia...
Is there any evidence to support screening for and treating asymptomatic bacteruria for patient to undergo cardiothor...
should tamiflu be offered to critically ill patients. Please evaluate most recent study REMAP-CAP and other studies
What is the evidence behind cranberry and preventing UTI

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:Muna Said, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Based on available data, Fibryga appears comparable to cryoprecipitate for transfusion requirements, mortality, and adverse events in bleeding cardiac surgery patients, although comparative data specific to Fibryga are limited and most pooled estimates reflect multiple fibrinogen concentrates rather than Fibryga alone. Cost findings vary by setting: the FIBRES trial found similar 28-day hospital costs and no meaningful differences in length of stay (LOS) or resource utilization, with cost-eff...

The 2021 Society of Thoracic Surgeons (STS), Society of Cardiovascular Anesthesiologists (SCA), American Society of Extracorporeal Technology (AmSECT), and Society for the Advancement of Blood Management (SABM) update to the clinical practice guidelines on patient blood management recommends goal-directed transfusion algorithms incorporating point-of-care (POC) testing, including viscoelastic testing, to reduce periprocedural bleeding and transfusion in cardiac surgical patients (Class I, Level B-R). The guideline notes that POC-based viscoelastic testing algorithms have demonstrated reductions in allogeneic blood product transfusions in high-risk cardiovascular surgery patients. In a large prospective multicenter study involving more than 7,000 cardiac surgery patients, implementation of a viscoelastic testing-based transfusion algorithm in combination with platelet function testing significantly reduced red blood cell and platelet transfusions compared with preimplementation pract...

READ MORE→

A search of the published medical literature revealed 6 studies investigating the researchable question:

Please provide a data summary for the use of Fibryga in cardiac surgery for use by anesthesia during the procedure as an alternative to cryoprecipitate or IFC in terms of clinical outcomes for differences in factor utilization, cost savings, LOS, time in OR, and bleeding outcomes

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Ann Thorac Surg. 2021;112(3):981-1004. doi:10.1016/j.athoracsur.2021.03.033
[2] Casselman FPA, Lance MD, Ahmed A, et al. 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP. Eur J Cardiothorac Surg. 2025;67(5):ezae352. doi:10.1093/ejcts/ezae352
[3] Chen Y, Yang W, Zhao C, et al. Treatment effects of fibrinogen concentrates vs. cryoprecipitate for correcting hypofibrinogenemia in cardiac surgery patients: a systematic review and meta-analysis. Front Cardiovasc Med. 2025;12:1671405. Published 2025 Oct 17. doi:10.3389/fcvm.2025.1671405

InpharmD's Answer GPT's Answer

Author:Kevin Shin, PharmD, BCPS + InpharmD™ AI LEARN MORE 

There is a paucity of data on differences in withdrawal between benzodiazepine agents. Generally, benzodiazepine withdrawal can start within 10-12 hours of discontinuation (especially with shorter-acting agents); however, longer-acting benzodiazepines may take days before withdrawal phenomena appear. The withdrawal symptoms typically peak to acute withdrawal 2 weeks after discontinuing the benzodiazepine; higher doses and length of treatment are associated with more severe withdrawal symptoms...

According to the American Addiction Centers, benzodiazepine withdrawal symptoms typically start within 24 hours of treatment and can last from a few days to several months, depending on the length of abuse and strength of the benzodiazepine(s) used. The occurrence of withdrawal is dependent on the agent’s half-life and the amount of time it takes for the drug to leave the bloodstream. For shorter-acting benzodiazepines (e.g., alprazolam), withdrawal may start within 10 to 12 hours of stopping the medication, whereas with longer-acting benzodiazepines (e.g., diazepam), it may take a few days for symptoms to appear. In general, the early withdrawal phase usually starts within a few hours to a few days of stopping the medication and may last several days. Around 2 weeks after stopping a benzodiazepine, acute withdrawal may begin, which constitutes the bulk of withdrawal symptoms. Risk factors for increased benzodiazepine withdrawal duration and intensity include the length of time taki...

READ MORE→

A search of the published medical literature revealed 4 studies investigating the researchable question:

Can you summarize the differences in benzodiazepine withdrawal severity, onset, and duration for the various benzodiazepine medications?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] American Addiction Centers. Benzo Withdrawal Symptoms, Timeline and Detox Treatment. Updated January 3, 2024. Accessed October 24, 2026. https://americanaddictioncenters.org/benzodiazepine/length-of-withdrawal
[2] Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118(2):69-86. doi:10.1111/j.1600-0404.2008.01004.x
[3] Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65 Suppl 5:7-12.
[4] Pétursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455-1459. doi:10.1111/j.1360-0443.1994.tb03743.x
[5] Hallfors DD, Saxe L. The dependence potential of short half-life benzodiazepines: a meta-analysis. Am J Public Health. 1993;83(9):1300-1304. doi:10.2105/ajph.83.9.1300

InpharmD's Answer GPT's Answer

Author:zophia@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Current guidelines recommend against routine screening for or treating asymptomatic bacteriuria (ASB) before elective nonurologic surgery, including cardiothoracic procedures. Available studies involving patients undergoing cardiac surgery, including coronary artery bypass grafting and valve replacement, have not demonstrated a significant reduction in postoperative infectious complications with preoperative ASB treatment. Although hematogenous dissemination of urinary pathogens is a potentia...

According to the 2019 Infectious Diseases Society of America (IDSA) guidelines, routine screening for or treatment of asymptomatic bacteriuria (ASB) before elective nonurologic surgery, including cardiothoracic surgery, is not recommended (strong recommendation, low-quality evidence). This recommendation was informed by three studies involving 3,167 surgical patients, including patients undergoing cardiac and vascular procedures, of whom 403 (12.7%) had ASB. Approximately 47% of patients with ASB received targeted antimicrobial treatment in addition to perioperative prophylaxis. The guideline concluded that the benefit of treating ASB beyond standard perioperative prophylaxis remains highly uncertain, with very low certainty regarding effects on postoperative infectious outcomes. Additionally, evidence is insufficient to determine whether expanding perioperative prophylaxis to cover urinary pathogens provides additional benefit. The guideline does not specifically evaluate whether A...

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

Is there any evidence to support screening for and treating asymptomatic bacteruria for patient to undergo cardiothoracic surgery? Is there any data to support decreasing risk of future endocarditis?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110. doi:10.1093/cid/ciy1121
[2] European Association of Urology. EAU Guidelines on Urological Infections. EAU Guidelines Office; 2026. Accessed October 26, 2026.
[3] Gómez-Ochoa SA, Espín-Chico BB. Lack of Benefit on Treating Asymptomatic Bacteriuria Prior to Cardiovascular Surgery: a Systematic Review and Meta-Analysis. Braz J Cardiovasc Surg. 2018;33(6):641-643. doi:10.21470/1678-9741-2018-0276

InpharmD's Answer GPT's Answer

Author:zophia@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines, which predate the 2026 REMAP-CAP trial, recommend oseltamivir for hospitalized patients with severe influenza, emphasizing initiation as soon as possible, preferably within 48 hours of symptom onset. Following REMAP-CAP, UK guidance continues to recommend oseltamivir as first-line treatment for critically ill patients, while Australian guidance strongly recommends against its use in critically...

A 2026 Centers for Disease Control and Prevention (CDC) clinician summary recommends initiating oral or enterically administered oseltamivir as soon as possible in all hospitalized patients with suspected or confirmed influenza, without awaiting laboratory confirmation; observational evidence indicates that benefit is greatest with early treatment but may persist when treatment is initiated more than 48 hours after symptom onset. At the time, no sufficiently powered, randomized, placebo-controlled trials of neuraminidase inhibitor monotherapy had been completed in hospitalized patients; however, observational studies have associated treatment with shorter hospitalization and reduced risks of intensive care unit (ICU) transfer, invasive mechanical ventilation, or death, although some studies have not demonstrated a mortality reduction. Standard-dose oseltamivir achieves therapeutic concentrations in critically ill adults, including limited data involving administration through gastri...

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

should tamiflu be offered to critically ill patients. Please evaluate most recent study REMAP-CAP and other studies

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. March 10, 2026. Accessed August 17, 2026.
[2] World Health Organization (WHO). Clinical practice guidelines for influenza. September 12, 2024. Accessed August 17, 2026.
[3] UK Health Security Agency. Guidance on Use of Antiviral Agents for the Treatment and Prophylaxis of Seasonal Influenza. Updated October 23, 2026. Accessed October 27, 2026. https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-of-seasonal-influenza
[4] Australian Living Evidence Collaboration. Drug Treatments for People With Influenza Who Are Critically Ill: Australian Guideline. Version 1.2. Updated October 12, 2026. Accessed October 27, 2026. https://livingevidence.org.au/influenza/
[5] Bay P, Martin-Loeches I, Haudebourg AF, et al. How to manage antivirals in critically ill patients with influenza?. Clin Microbiol Infect. 2025;31(7):1157-1165. doi:10.1016/j.cmi.2025.04.002
[6] Gao Y, Guyatt G, Uyeki TM, et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;404(10454):753-763. doi:10.1016/S0140-6736(24)01307-2
[7] Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404. doi:10.1016/S2213-2600(14)70041-4

InpharmD's Answer GPT's Answer

Author:Naveed Aijaz, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Published evidence supports cranberry products for preventing urinary tract infections (UTIs) in women with recurrent UTIs, with systematic reviews also reporting benefit in children and individuals susceptible to UTIs following interventions. Current AUA/CUA/SUFU guidelines recommend offering cranberry as an option for prophylaxis in women with recurrent UTIs, classified as a moderate recommendation with Grade B evidence. However, individual trial results vary, and pooled evidence does not s...

A 2025 American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/CUA/SUFU) guideline update recommends that clinicians offer cranberry as an option for prophylaxis in women with recurrent urinary tract infections (UTIs), classified as a moderate recommendation with Grade B evidence. The guideline describes proanthocyanidins (PACs) as the proposed mediators of cranberry’s ability to prevent bacterial adhesion to the urothelium. A cited meta-analysis supports cranberry supplements standardized to at least 36 mg of PACs, reporting greater effectiveness in reducing UTI recurrence than products containing less than 36 mg; however, many commercial products lack documented validation of PAC dosage. Two recent randomized controlled trials involving 218 participants demonstrated reduced UTI rates with cranberry prophylaxis compared with placebo. Additionally, a 2024 systematic review and network meta-analys...

READ MORE→

A search of the published medical literature revealed 18 studies investigating the researchable question:

What is the most recent evidence regarding use of cranberry products and efficacy for UTI prevention?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Ackerman AL, Bradley M, D'Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 2026;215(1):3-12. doi:10.1097/JU.0000000000004723
[2] Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;11(11):CD001321. Published 2023 Nov 10. doi:10.1002/14651858.CD001321.pub7
[3] Moro C, Phelps C, Veer V, et al. Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2024;10(6):947-957. doi:10.1016/j.euf.2024.07.002
[4] Xiong Z, Gao Y, Yuan C, Jian Z, Wei X. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review. Front Nutr. 2024;11:1422121. Published 2024 Nov 28. doi:10.3389/fnut.2024.1422121
[5] Bryce MR, Bryce CJC. Cranberry products to reduce recurrence of urinary tract infections in older people: a narrative review. Asian Journal of Gerontology & Geriatrics. 2022;17(2):60-63. doi:10.12809/ajgg-2022-554-ra
[6] Xia JY, Yang C, Xu DF, Xia H, Yang LG, Sun GJ. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One. 2021;16(9):e0256992. Published 2021 Sep 2. doi:10.1371/journal.pone.0256992
[7] Fu Z, Liska D, Talan D, Chung M. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr. 2017;147(12):2282-2288. doi:10.3945/jn.117.254961
[8] Chughtai B, Thomas D, Howell A. Variability of commercial cranberry dietary supplements for the prevention of uropathogenic bacterial adhesion. Am J Obstet Gynecol. 2016;215(1):122-123. doi:10.1016/j.ajog.2016.03.046

Why choose InpharmD™?

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


—   Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


—   Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


—   Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free